Moreover, the synergistic effect of gefitinib and BYL719 was also confirmed in the 3D cell culture model, the in vivo model, as well as in the organoid model from a lung adenocarcinoma patient with EGFR, ErbB2, PIK3CA mutations and MET amplification. Here, EGFR is linked to lung adenocarcinoma.